Combination therapy with Ezetimibe and Gemfibrozile on post-prandial hypertriglyceridemia

Not Applicable

• Conditions: Diabetes.; Non-insulin-dependent diabetes mellitus

• Registration Number: IRCT201105311179N5
• Lead Sponsor: Zanjan Metabolic Research Center, Zanjan University of medical science

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

The average age of 20-65-HbA1C <8%-hypertriglycemia>250mg/dl?Patients with DM type 2

Exclusion criteria:
Treating with antilipid agents, thyroid disease, acute or chronic liver disease, association with other endocrine disease like Acromegaly or cushing , renal dysfunction (GFR<60), Hypertriglyceridemia>1000 and LDL >190mg/dl

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ipid profile. Timepoint: 6 weeks. Method of measurement: labratory.

Secondary Outcome Measures

Name	Time	Method
Apo protein B. Timepoint: 6 weeks. Method of measurement: labratory.;Apo protein A. Timepoint: 6 weeks. Method of measurement: labratory.